A best evidence topic was written according to a structured protocol. The question addressed was whether totally endoscopic coronary artery bypass (TECAB) is safe, effective and feasible. A total of 171 papers were found, of which eight represented the best evidence. The authors, date, journal, study type, population, main outcome measures and results are tabulated. The da Vinci robotic system was utilized in seven retrospective studies and one multicentre prospective trial, comprising 724 patients undergoing TECAB. Patient-related outcomes, including the incidence of major adverse cardiac events, graft patency and survival, were investigated. From the studies evaluated, TECAB appears to be safe operation with low complication rates and excellent early-and mid-term graft patencies. The incidence of internal thoracic artery injury was documented in four studies and ranged from 0 to10%. Re-exploration for bleeding was necessary in 1-15% of patients. Conversion to open techniques was performed in 0-24% of cases. There was no in-hospital mortality in the majority of studies, but this reached 2.1% in a large series of 228 patients. Target-vessel reintervention rates varied between 0 and 12.1% according to the institutional experience. Pre-and post-discharge graft patencies were excellent at 93-100 and 92-100%, respectively. Intraoperative variables, such as time taken for internal thoracic artery harvest, anastomosis, cross-clamp, cardiopulmonary bypass (CPB) and the overall operation were as follows: internal thoracic artery harvest time (range 5-187 min), anastomosis time (range 6-82 min), cross-clamp time (range 30-223 min), CPB time (range 41-268 min) and operative time (range 84-600 min). TECAB is a technically demanding and time-consuming procedure associated with a significant learning curve. Proctoring and structured training programmes are currently supported by European and international societies to encourage wider uptake of the procedure. In conclusion, TECAB represents a feasible alternative to conventional coronary artery bypass in selected patients. It is associated with low morbidity and excellent mid-term graft patency. Larger, prospective and multicentre trials are required to assess the long-term and patient-reported outcomes of TECAB.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You attend a multidisciplinary meeting to discuss the surgical management of a 67-year old male with single-vessel disease of the left anterior descending (LAD) artery. Minimally invasive direct coronary artery bypass (MIDCAB) is suggested as the operation of choice, owing to excellent graft patency and survival outcomes. Totally endoscopic coronary artery bypass (TECAB) is mentioned as another suitable technique, but there are concerns regarding the long-term results of this procedure. You perform a literature search to investigate the safety, feasibility and efficacy of TECAB.
SEARCH OUTCOME
The search strategy identified 187 papers, of which eight provided the best evidence to answer the clinical question. Only TECAB papers published within the last 10 years were selected (Table 1) .
RESULTS
In most studies evaluated, patients referred to first-time singlevessel coronary artery bypass graft (CABG) were eligible for TECAB. Exclusion criteria included previous thoracic surgery, morbid obesity, haemodynamic instability, acute myocardial infarction or stroke, renal failure, severe respiratory compromise and peripheral vascular disease, precluding single-lung ventilation and femoral cannulation, respectively.
In the Gao et al.' [2] retrospective study of 58 single-vessel TECAB patients, there was no ITA injury. Two cases were converted to MIDCAB (3%), with one re-exploration (1.7%) for bleeding. Graft patency predischarge and at 3, 6 and 12 months was 100%.
Argenziano et al.
[3] reported a 5.9% incidence of major adverse cardiac events (MACEs) in their multicentre prospective trial of 85 single-vessel TECAB patients. Five patients (6%) required conversion to sternotomy following internal thoracic artery (ITA) injury, anastomotic bleeding or poor intraoperative graft flow. Target-vessel reintervention was necessary in four patients (4.7%). Three-month angiography demonstrated anastomotic occlusion in two cases and >50% stenosis in four cases. Nevertheless, overall freedom from reintervention or graft failure was 91%.
de Cannière et al. [4] investigated 228 patients, 90% with single-vessel disease, undergoing on-or off-pump TECAB in a multicentre retrospective study. Twenty-seven were converted to non-robotic techniques in the on-pump group, due to cannulation issues in 55%. The majority of 37 off-pump conversions were attributed to patient-related factors and anastomotic bleeding. All-cause mortality was lowest with on-pump at 2.1%. Six patients (2.6%) required target-vessel reintervention. Overall efficacy, as defined by angiographic patency and stress echocardiography, was 97%.
In their retrospective study, Dogan et al. [5] demonstrated 100% predischarge graft patency among the first 22 (of 45) patients undergoing single-or double-vessel TECAB. Ten required conversion to left mini-thoracotomy or sternotomy. Other complications included anastomotic bleeding (4.4%), ITA injury (2.2%), myocardial infarction (2.2%) and retrograde aortic dissection (2.2%).
Kappert et al. [6] retrospectively analysed 41 patients with high-grade LAD lesions; the first eight underwent arrested-heart TECAB, whereas the remainder had beating-heart procedures. Fourteen patients underwent postoperative angiography and 5 (12.2%) required LAD reintervention. Two suffered myocardial infarction within the follow-up period, but neither was attributed to the bypassed target vessels. There was no in-hospital mortality, and overall survival was 92.7%, with 82.9% freedom from MACCE.
Three-month graft patency was 92% among 13 single-vessel TECAB patients (11 off-pump) in the retrospective study by Mishra et al. [7] . There was one reoperation for bleeding; no other complications or mortality were reported.
Srivastava et al. [8] retrospectively analysed 214 patients undergoing single-vessel, double-vessel or triple-vessel beatingheart TECAB. There were no reported ITA injuries. Five patients (2.1%) in the single-vessel and 12 (5%) in the double-vessel group required conversion to mini-thoracotomy; two (1%) required re-exploration for bleeding. Complications included new-onset atrial fibrillation in 10% and postoperative angina in 1%. In 182 of a total of 239 grafts (82%) evaluated, 100% were patent. Overall clinical freedom from graft failure and reintervention was 98.6%.
Bonatti et al. [9] retrospectively investigated 40 patients undergoing arrested-heart TECAB for single-vessel disease using remote-access perfusion CPB. Undesirable technical issues arose in 20 cases (50%), including remote-access perfusion problems (23%), anastomotic bleeding (18%), ITA injury (10%) and port bleeding (8%). Revision was necessary in 30% (6 of 20) in which technical challenges arose. Nevertheless, there was no operative mortality or target-vessel reintervention, and cumulative survival was 100%.
Many studies describe a significant TECAB 'learning curve', reflected by extended operating times (3-5 h) for single-vessel bypass, but exceeding 8 h for triple-vessel procedures. However, with increasing surgical experience, there is a general trend towards shorter ITA harvest, anastomosis, cross-clamp and cardiopulmonary bypass times.
CLINICAL BOTTOM LINE
The studies examined are generally of low evidence level and limited by small patient populations, short durations of follow-up and lack of comparison against alternatives such as MIDCAB. In their 2005 guidance, the National Institute for Clinical Excellence (NICE) highlighted the inadequate safety and efficacy data regarding TECAB (http://publications.nice.org.uk/totally-endoscopic-roboticallyassisted-coronary-artery-bypass-grafting-ipg128). However, both on-and off-pump TECAB demonstrate promising safety outcomes, with a low incidence of MACE. TECAB represents a major paradigm change, demanding a different, complex skill set from open cardiac surgery. The complications observed here may reflect early experience, associated with a substantial learning curve. Indeed, intraoperative conversion rates may decline with increasing experience. Furthermore, conversion does not compromise graft patency, which remains excellent in the shortand mid-terms. Careful patient selection, target-vessel assessment and team-training are mandatory. Although TECAB is time-consuming and technically demanding, it is feasible. Technological developments, e.g. in anastomotic devices and endoscopic stabilizers, will further enhance this procedure. Proctoring and the provision of structured educational programmes will facilitate the wider adoption of TECAB within the cardiac surgical community. In conclusion, TECAB is a safe alternative to conventional CABG, offering excellent graft patency in highly selected patient groups. Larger, prospective and multicentre trials are required to confirm the encouraging results of TECAB and report on patient-reported outcomes, which remain to be addressed. 
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